AZNAstraZenecaFinished
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Hepatocellular Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 908 (final count)
- Started
- Apr 29, 2019
- Main results expected
- May 15, 2026
- Fully finished
- Jul 27, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recurrence-free survival (RFS) for Arm A vs Arm C
Measured over: Up to 49 months after first patient randomized
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03847428 · record last updated 2026-10-08 · checked 2026-11-09 15:47 UTC